Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists

Enhance your understanding of optimizing BTK inhibitor therapy in chronic lymphocytic leukemia. Learn more about individualizing therapy, monitoring for and managing adverse events, and strategies to address barriers to treatment access and adherence through an on-demand webcast, expert-authored ClinicalThought commentary, audio podcast, and downloadable slides.

Share

Program Content

Events

Activities

BTKis in CLL
Optimizing BTK Inhibitor Therapy in CLL: Updates and Strategies for Oncology Pharmacists
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 06, 2025

Expires: May 05, 2026

AEs With BTKis
Adverse Event Management, Adherence, and Drug–Drug Interactions With BTK Inhibitors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 06, 2025

Expires: May 05, 2026

Provided by

ProCE Banner
ProCE Banner

Provided by ProCE, LLC in collaboration with Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly